ArticleGastroenterology2022
Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry.
Abstract read
In one paragraph
Article in Gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- COVID-19 AND IBD: LOOK BEYOND THE VIRUS. A SYSTEMATIC REVIEW AND META-ANALYSIS FOCUSED ON BIOLOGIC THERAPY CONTINUITY.Arquivos de gastroenterologia · 2026Pooled it
- Increased failure of budesonide MMX for ulcerative colitis during the COVID-19 pandemic: a population-based study.Therapeutic advances in gastroenterology · 2026Article
- Durability of Antibody Responses to SARS-CoV-2 Vaccination over 12 Months in Pediatric Inflammatory Bowel Disease.Vaccines · 2025Article
- Efficacy and safety of remdesivir and favipiravir in COVID-19 patients - A systematic review and meta-analysis.Journal of family medicine and primary care · 2025Review
- Article
- Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases.Alimentary pharmacology & therapeutics · 2025Article
- Navigating SARS-CoV-2-related immunopathology in Crohn's disease: from molecular mechanisms to therapeutic challenges.Virology journal · 2024Review
- Forecasting the Incidence and Prevalence of Inflammatory Bowel Disease: A Canadian Nationwide Analysis.The American journal of gastroenterology · 2024Article
- COVID-19 vaccination safety and associated health care utilization among adults with inflammatory bowel disease - a population-based self-controlled case series analysis.BMC gastroenterology · 2024Article
- Vaccine Acceptance in Patients with Inflammatory Bowel Disease: Lessons Learned from the COVID-19 Pandemic.Vaccines · 2024Article
- Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease.Digestive diseases and sciences · 2024Article
- A Practical Update on COVID-19 and Inflammatory Bowel Disease: COVID-19 Disease Risk and Vaccine Safety and Efficacy.Gastroenterology & hepatology · 2024Article
- Cytokine Storm-Induced Thyroid Dysfunction in COVID-19: Insights into Pathogenesis and Therapeutic Approaches.Drug design, development and therapy · 2024Review
- Symptoms and Severity of COVID-19 in Patients with Immune-Mediated Inflammatory Diseases: Experience of a University Medical Center.Autoimmune diseases · 2024Article
- Using Multi-Modal Electronic Health Record Data for the Development and Validation of Risk Prediction Models for Long COVID Using the Super Learner Algorithm.Journal of clinical medicine · 2023Article
- Venous Thromboembolism After COVID-19 Infection Among People With and Without Immune-Mediated Inflammatory Diseases.JAMA network open · 2023Article
- Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan: A multicenter study.Journal of the Formosan Medical Association = Taiwan yi zhi · 2023Article
- Trajectory analyses to identify persistently low responders to COVID-19 vaccination in patients with inflammatory bowel disease: a prospective multicentre controlled study, J-COMBAT.Journal of gastroenterology · 2023Article
- COVID-19 Outcomes in Inflammatory Bowel Disease Hospitalized Patients: A Comprehensive Analysis Using the National Inpatient Sample.Gastroenterology research · 2023Article
- The 2023 Impact of Inflammatory Bowel Disease in Canada: COVID-19 and IBD.Journal of the Canadian Association of Gastroenterology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Ryan C UngaroThe Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: ryan.ungaro@mssm.edu.
Erica J BrennerDivision of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: erica.brenner@unchealth.unc.edu.
Manasi AgrawalThe Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Xian ZhangDivision of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Michael D KappelmanDivision of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Jean-Frederic ColombelThe Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group
Funding
Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6MDIGESTIVE DISEASES EPIDEMIOLOGY TRAINING PROGRAMT32DK007634 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1990 to 2026
$7.4MEarly-life Risk Factors for Inflammatory Bowel DiseaseK23DK129762 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI AGRAWAL, MANASI · 2021 to 2025
$951kAssessing Predictors of Response to Anti-Tumor Necrosis Alpha Therapy in Early Crohns DiseaseK23DK111995 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI UNGARO, RYAN · 2019 to 2023
$948kNCATS NIH HHS UL1 TR002489NIDDK NIH HHS K23 DK111995NIDDK NIH HHS K23 DK129762NIDDK NIH HHS T32 DK007634
Abstract
PubMed holds no abstract for this paper.
Indexed as
RegistriesSARS-CoV-2Adrenal Cortex HormonesCOVID-19HumansInflammatory Bowel DiseasesMesalamineSeverity of Illness IndexSulfasalazineTumor Necrosis Factor-alphaAdrenal Cortex HormonesMesalamineSulfasalazineTumor Necrosis Factor-alpha
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.